News

NANBIOSIS U27 propose a mew method for assessing nonlinear cardiorespiratory interactions

Researches of NANBIOSIS Unit 27 High Performance Computing, S. Kontaxis, J. Lázaro, E. Gil, P. Laguna, and R. Bailón are the authors of an article recently published by IEEE Transactions Biomedical Engineering

Alternations of cardiorespiratory interactions are related to Autonomic Nervous System (ANS) dysfunction and physiological regulation of the Heart Rate Variability (HRV) in cardiovascular diseases. In this study, a method for assessing nonlinear cardiorespiratory interactions is proposed, quantifying the Quadratic Phase Coupling (QPC) between respiration and HRV. Quadratic cardiorespiratory couplings are studied during a tilt table test protocol on young healthy subjects. Results show a significant reduction of QPC between respiration and HRV during head-up tilt position compared to early supine suggesting that the proposed technique is able to track nonlinear cardiorespiratory couplings during ANS changes.

Article of reference:

S. Kontaxis, J. Lázaro, E. Gil, P. Laguna, R. Bailón (2019)Assessment of Quadratic Nonlinear Cardiorespiratory Couplings During Tilt Table Test by Means of Real Wavelet Biphase, IEEE Transactions Biomedical Engineering. vol. 66, n. 1, pp. 187-198 doi: 10.1109/TBME.2018.2821182

• Read More

NANBIOSIS unit 13 participation at the VIII Conference of Young Researchers of I3A-UZ

Next Thurstday, June 6th, the “Aragón Engineering Research Institute” (I3A) of University of Zaragoza will hold the “VIII Conference of Young Researchers” at the Conference Room Building. R & D (block 1, 1st floor)

Researchers of NANBIOSIS unit U13 Tissue & Scaffold Characterization Unit will present their works

In the oral presentations section, Mohamed H. Doweidar will talk about Cell behavior under hypoxic conditions. Computational 3D model.

In the posters section in the area of BIOMEDICAL ENGINEERING the researchers of unit 13 will present the following results.

Design of a microfluidics system for the simulation of the formation of atheromatous plaque. Itziar Ríos Ruiz, Sara Oliván García, Miguel Ángel Martínez Barca, Estefania Peña Baquedano.

Mechanobiological modeling of the formation of atheromatous plaque in the carotid artery of a specific patient. Patricia Hernández López, Myriam Cilla Hernández, Miguel Ángel Martínez Barca, Estefania Peña Baquedano.

• Read More

Mechanism of interaction of a material (pharmaceutical, food, construction, chemical, etc.) with moisture or with any organic vapor.

Next June 11, 2019, from 09:30h to 17:00h, will take place in Eureka Building – Parc de Recerca, UAB (Barcelona), a Scientific-Theoretical / Practical Workshop on: DYNAMIC SORPTION OF VAPORS (DVS – DYNAMIC VAPOR SORPTION) AND CHARACTERIZATION OF MATERIALS (iGC / SEA – INVERSE GAS CHROMATOGRAPHY / SURFACE ENERGY ANALYZER) FOR THE ANALYSIS OF THE SORTION OF WATER AND ORGANIC VAPORS, AND CHARACTERIZATION OF MATERIALS AND SURFACES.

The event is organized by IESMAT, S.A. in collaboration with Nanomol Technologies SL, the Institute of Materials Science of Barcelona (ICMAB-CSIC), Surface Measurement Systems (SMS) and the Center for Biomedical Research in Network (CIBER)/NANBIOSIS, includes theoretical presentation DVS (Dynamic Vapor Sorption) technologies and iGC-SEA (Inverse Gas Chromatography – Surface Energy Analyzer).

This workshop, addressed to researchers and/or technicians interested in knowing the mechanism of interaction of a material (pharmaceutical, food, construction, chemical, etc.) with moisture or with any organic vapor, and DVS users, includes: Presentation of equipment and instrumentation of Surface Measurement Systems (SMS) distributed by Specific Instrumentation of Materials (IESMAT). Presentation of users of dynamic vapor sorption equipment. Demonstration of hardware and software of the DVS Intrinsic equipment.

FREE REGISTRATION– until full capacity is reached. To formalize it, contact Ms. Estefanía Écija (estefania.ecija@iesmat.com; 91 650 8005), before June 6th, indicating name, company, telephone and e-mail.

• Read More

Quantification of Ventricular Repolarization Variation for Sudden Cardiac Death Risk Stratification in Atrial Fibrillation

ATRIAL fibrillation (AF) is the most prevalent sustained arrhythmia and it has become one of the most important public health issues in developed countries. It is expected to double its incidence by 2030 [1], [2], representing the major cause of hospitalizations in elderlies (≥65 years), together with chronic heart failure

Alba Martín-Yebra and Juan Pablo Martínez, scientists of NANBIOSIS U27 High Performance Computing, have led the research that proves that it is possible to stratity AF patients at risk of sudden cardiac death (SCD) what could help cardologists to implement better solutions.

The computation was performed by the ICTS NANBIOSIS, specifically by the High Performance Computing Unit of the CIBER-BBN at the I3A-University of Zaragoza.

Atrial fibrillation (AF) rhythm is characterized by an irregular ventricular response, preventing the use of standard ECG-derived risk markers based on ventricular repolarization heterogeneity under this particular condition. In this study, the authors proposed new indices able to quantify repolarization variations in AF patients assessing their stratification performance in a chronic heart failure population with AF. Results showed that patients with enhanced ventricular repolarization variation computed in terms of the proposed indices were successfully associated to a higher sudden cardiac death incidence in our study population. In addition, risk assessment based on the combination of the proposed indices improved stratification performance compared to their individual potential. In conclusion, the study proves that using a simple ambulatory ECG recording, it is possible to stratify AF patients at risk of SCD, which may help cardiologists in adopting most effective therapeutic strategies, with a positive impact in both the patient and healthcare systems

Article of reference:

A. Martín-Yebra, P. Laguna, I. Cygankiewicz, A. Bayés-de-Luna, E. G.
Caiani, J. P. Martínez Quantification of Ventricular Repolarization Variation for Sudden Cardiac Death Risk Stratification in Atrial Fibrillation. IEEE J Biomed Health Inform, v.. 23, n. 3, pp 1049-
doi: 1057.10 1109/JBHI.2018.2851299

• Read More

Preclinical molecular imaging and its application to biomedical research

During the days 22-24 of May is taking place in Madrid the 3rd Workshop of introduction to the preclinical molecular image and its application to biomedical research,. The wokshop has been organized by the Health Research Institute of the Gregorio Marañón Hospital, the Complutense University of Madrid and the Madrilenian Network of nanomedicine in molecular imaging (RENIM-CM).

The program counts with theoretical sessions of introduction to the physical foundations of each one of the modalities of image and its applications to preclinical biomedical research, as well as practical demonstrations of said image techniques.

Ibane Abásolo, Scientific Coordinator of Unit 20 of NANBIOSIS In Vivo Experimental Platform, introduced the in vivo optical imaging applications, explaining the research carried out at her research group at Vall d’Ebron Hospital Research Institute (VHIR) and NANBIOSIS U20 created by CIBER-BBN and VHIR, applied to projects as the H2020 Smart4Fabry and NoCanTher

NANBIOSIS U20 In vivo Experimental Platform has three different sections, a Molecular Imaging section for in vivo, ex vivo and in vitro imaging studies (fluorescence, bioluminescence and X-rays), a preclinical animal model section and a preclinical histology section.

• Read More

An Eskimo in the desert

An Eskimo in the desert is the title of the talk that Ignacio Ochoa Researcher of NANBIOSIS U13 Tissue & Scaffold Characterization Unit is giving today at the Pint of Science Festival in Zaragoza at 19:00.

One of the greatest advances in biomedicine was to achieve, at the end of the 19th century, maintain human cells outside the body in order to study them. This breakthrough has allowed us, for example, to discover new drugs and evaluate the toxicity of many compounds. Unfortunately, this progress has hardly evolved over these 125 years. However, the arrival of microfluidic technology has allowed us to simulate much better what actually happens in our body. This new advance will revolutionize biomedicine, bringing it closer to the goal of personalized medicine

As Iñaki has explained to NANBIOSIS “Cells are accustomed to being in a specific environment in our body (mechanical, chemical, electrical, etc.) and, when we take them out of that environment to study them in the laboratories they stop working in a similar way as they did in vivo. This change of functioning sometimes generates false positives in the study of efficacy of new drugs and generates delays and excessive costs in the development of new treatments. Thanks to the Organ on Chip technology, we can better simulate in the laboratory the environment of the cells under physiopathological conditions (rigidities, gradients, flow or the presence of different cell types) and obtain results closer to the clinic”.

• Read More

DEVELOPING A SENSOR FRAMEWORK FOR MINIMALLY INVASIVE SURGERY

Francisco Miguel Sánchez Margallo, Scientific Director of the Minimally Invasive Surgery Center ‘Jesús Usón’ and Deputy Director of NANBIOSIS, leads, together with Thomas Malone, of the Massachusetts Institute of Technology (MIT), in the United States, the project selected by the MIT program -Spain ‘La Caixa’ Foundation Seed Fund “Developint a sensor framework for minimally invasive surgery”.

The project seeks to develop a system of sensors to analyze health parameters of the surgeon, such as his physiological and ergonomic state, as well as the interaction between this and the patient during surgery. It is a disruptive research project on sensors to improve the health of the surgeon and the quality of surgery. NANBIOSIS units at JUMISC will play an important role in the development of the project.

This program was born with the aim of promoting the interrelation between Spanish research groups of excellence and those of MIT. The initiative aims to generate synergies and facilitate collaboration in international projects with a pioneering entity at the international level such as MIT.

The collaboration with MIT brings great value to Spanish research, since it is one of the best international research institutions. Among the professors about 80 Nobel prizes are counted, and its students have promoted more than 30,000 companies.

• Read More

Multiparametric MR approaches for non-invasive glioblastoma therapy response follow-up (MAGRes)

Ana Paula Candiota, Scientific coordinator of U25 of NANBIOSIS, is the IP of the granted project Multiparametric MR approaches for non-invasive Glioblastoma therapy response follow-up (MAGRes), selected for funding in the ATTRACT call https://attract-eu.com/the-project/

The kick-off meeting for is taking place at CERN, Switzerland, days 20-21th May with talks of all selected projects. Unit 25 will have a relevant role in the development of MAGRes. MRI/MRSI from preclinical brain tumors will be acquired at NANBIOSIS U25, NMR: Biomedical Applications I

• Read More

Job Vacancy for position of Project Manager at CIBER

Scientist aiming at developing a career in project management is required for a European Project in the field of biomedical research; working with NANBIOSIS ICTS (Scientific infraestructure of CIBER-BBN). The position requires good command of English and strong skills in coordinating researchers.

Applications must be filed at CIBER’s web portal untill May 22.

• Read More

Safe-N-Medtech kicks off in Bilbao

The Safe-N-MedTech European Project kcks off in Bibao to create an open innovation platform that accelerates the development of medical devices based on nanotechnologies.

During 2 and 3 of May took place in Bilbao, at the University of the Basque Country, the kick off meeting of the European project Safe-N-Medtech organized by Osteba, the HTA Unit of the Ministry of Health of the Basque Country (Spain) in collaboration with BIOPRAXIS-BIOKERALTY.

Safe-N-Medtech, counts with 28 partnerts coordinated by TECNAN (Navarran company with great experience in Nano products), together with BIOPRAXIS-BIOKERALTY, the research branch of the global health companies Keralty and Praxis. The new project is part of the Open Innovation Test Bed initiative (OITB) launched by the European Commission with the aim of accelerating the development of medical devices based on nanotechnologies in Europe and abroad. The project has a European funding of 15 million euros.

CIBER-BBN participates as a partner in the Safe-N-Medtech throught its Scientific Infraestructure, the ICTS NANBIOSIS. Several units of NANBIOSIS from CIBER-BBN and JUMISC wiil carry out some of the F/Q, in vivo and in vitro characterizations applied to pilot test cases, NANBIOSIS is the leader of WP3 Preclinical Research in nano-enabled MTs.

Society and clinical practice raise a growing demand for new biomaterials, ICTs, medical devices and in vitro diagnostics (Medical Technologies-MTs) based on micro and nanotechnologies. In addition to the challenge of time, new technologies are subject to other pressing factors, such as qualification, regulation, cost, biocompatibility and the need to be applicable throughout the world. Medical devices based on nanotechnologies can be applied in almost all medical areas, with an important presence in areas such as cancer, regenerative medicine, advanced therapies, neurology, cardiology, orthopedics and dentistry.

The initiative aims to build an open innovation platform to offer companies and reference laboratories the capabilities, knowledge, networks and services necessary for the development, testing, evaluation, improvement and exploitation of the market of medical devices and diagnostic based in nanotechnology. This platform will offer a multidisciplinary and market-oriented innovation approach for SMEs, health care providers and industries, accelerating the transfer to the market of these new medical devices. During the first years of project work, the partners will develop their services and test them in different case studies, so that, Safe-N-Medtech OITB can become a sustainable and competitive services platform for companies to accelerate their developments according to the necessary regulatory requirements and ensure the safety and effectiveness of their medical devices based on nanotechnologies.

• Read More

You are here : Home / News (Page 51)